There were no apparent associations with disease activity, prediction of treatment response or radiographic progression, and further studies in larger patient samples are needed to understand the role of ACPA reactivities in patients with RA classified according to the 2010 ACR/EULAR criteria. This evidence concerns the gene PRTN3 and rheumatoid arthritis.